Acrux

Acrux Gross Profit

The Gross Profit of Acrux (ACR.AX) as of Oct 20, 2026 is 4.21 M AUD. In the previous year, Gross Profit was 1.19 M AUD — a change of 253.45% (higher).

Gross Profit

4.21 MAUD

YoY

253.45%

Last updated:

Gross Profit of Acrux is 2026 4.21 M AUD. Gross Profit of Acrux was 2025 1.19 M AUD. It decreases by 253.45% higher compared to the previous year.

The Acrux Gross Profit history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Profit
Date
Gross Profit
Jan 1, 2019
-4.49 M AUD
Jan 1, 2020
-3.76 M AUD
Jan 1, 2021
-7.59 M AUD
Jan 1, 2022
-4.65 M AUD
Jan 1, 2023
1.95 M AUD
Jan 1, 2024
1.13 M AUD
Jan 1, 2025
1.19 M AUD
Jan 1, 2026
4.21 M AUD
The Acrux Gross Profit history
YEARGross ProfitYoY
4.21 MAUD+253.45%
1.19 MAUD+4.94%
1.13 MAUD-41.73%
1.95 MAUD-141.83%
-4.65 MAUD-38.72%
-7.59 MAUD+101.94%
-3.76 MAUD-16.32%
-4.49 MAUD-5,447.62%
84,000.00AUD-99.59%
20.56 MAUD-21.35%
26.14 MAUD+9.81%
23.80 MAUD-53.58%
51.28 MAUD+241.48%
15.02 MAUD+70.69%
8.80 MAUD-90.18%
89.60 MAUD+63.20%
54.90 MAUD+8,346.77%
650,000.00AUD-85.54%
4.50 MAUD+55.20%
2.90 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrux Revenue

Acrux Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
1.25 M AUD
-12.08 M AUD
-9.47 M AUD
Jan 1, 2021
1.34 M AUD
-16.25 M AUD
-12.63 M AUD
Jan 1, 2022
1.72 M AUD
-12.97 M AUD
-9.83 M AUD
Jan 1, 2023
8.43 M AUD
-3.39 M AUD
-764,000.00 AUD
Jan 1, 2024
5.09 M AUD
-8.58 M AUD
-5.80 M AUD
Jan 1, 2025
1.19 M AUD
-8.97 M AUD
-5.95 M AUD
Jan 1, 2026
4.64 M AUD
-2.14 M AUD
-604,000.00 AUD
Jan 1, 2027 (e)
14.20 M AUD
5.18 M AUD
4.23 M AUD

Acrux Margins

Acrux stock margins

The Acrux margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Acrux. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Acrux.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
-300.00 %
-963.85 %
-755.87 %
Jan 1, 2021
-567.76 %
-1,215.48 %
-944.58 %
Jan 1, 2022
-270.62 %
-754.28 %
-572.08 %
Jan 1, 2023
23.09 %
-40.22 %
-9.06 %
Jan 1, 2024
22.27 %
-168.43 %
-113.93 %
Jan 1, 2025
100.00 %
-753.95 %
-499.58 %
Jan 1, 2026
90.57 %
-46.06 %
-13.01 %
Jan 1, 2027 (e)
90.57 %
36.46 %
29.76 %

Acrux Stock analysis

What does Acrux do? Acrux Ltd is an Australian pharmaceutical company specializing in the development and marketing of products in the dermatology field. The company was founded in 1998 and is headquartered in Melbourne. Its history begins with the development of a groundbreaking technology called the "Sprayform® Technology," which allows the administration of liquid medications in spray form, providing numerous advantages compared to traditional administration methods. Acrux obtained the first patent for this technology in 1999 and worked on bringing it to the market. Its business model focuses on licensing its Sprayform® Technology to third parties to advance the development and marketing of products in various therapeutic areas. The company has an experienced research and development team that collaborates closely with partners to develop tailored solutions and support the entire development process, ensuring that all products meet the highest quality standards and regulatory requirements. Acrux Ltd is divided into various divisions, including products for women, diabetes, pain and inflammation, as well as neurology and psychiatry. With its Sprayform® Technology, the company has developed unique therapeutic solutions that meet patients' needs. For example, a testosterone preparation for women has been developed that is simply applied as a spray and offers higher efficacy than traditional tablets. Another product is a fast-acting pain reliever that is administered through a nasal spray. Acrux Ltd also has partnerships with major pharmaceutical companies such as Eli Lilly, Johnson & Johnson, Pfizer, and Sanofi. These partnerships enable Acrux to market its technology globally and offer its customers a comprehensive portfolio of tailored solutions. The partner is granted exclusive rights to use the technology for specific products and markets, facilitating the development of new products and the expansion into new regions. Overall, Acrux Ltd has achieved a leadership position in the field of transdermal systems and transmucosal technologies through its innovative Sprayform® Technology. The company aims to further expand its leadership position by focusing on the development of new products and collaboration with partners. Acrux remains in constant exchange with the scientific community to incorporate the latest research and development insights into its products. Acrux is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrux stock

Gross Profit of Acrux is 4.21 M AUD in 2026.

Gross Profit of Acrux changed from 1.19 M AUD to 4.21 M AUD, representing a 253.45% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit Acrux since 2006 – with annual values, charts, and detailed analysis.

Gross Profit is the revenue remaining after deducting the cost of goods sold. It shows how efficiently a company uses its resources to produce goods or services.

Gross Profit's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Gross Profit's Acrux historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Acrux

All Key Metrics — Acrux